Francois Binette - Feb 13, 2024 Form 4 Insider Report for RENOVARO BIOSCIENCES INC. (RENB)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RENB	Option to Purchase Common Stock	Disposed to Issuer	-65K	-100%	0	Feb 13, 2024	Common Stock	65K	$2.38	Direct	F1, F2
transaction	RENB	Option to Purchase Common Stock	Award	+65K		65K	Feb 13, 2024	Common Stock	65K	$1.92	Direct	F2
transaction	RENB	Option to Purchase Common Stock	Disposed to Issuer	-65K	-100%	0	Feb 13, 2024	Common Stock	65K	$8.40	Direct	F2
transaction	RENB	Option to Purchase Common Stock	Award	+65K		65K	Feb 13, 2024	Common Stock	65K	$1.92	Direct	F2
transaction	RENB	Option to Purchase Common Stock	Disposed to Issuer	-40K	-100%	0	Feb 13, 2024	Common Stock	40K	$2.15	Direct	F2, F3
transaction	RENB	Option to Purchase Common Stock	Award	+40K		40K	Feb 13, 2024	Common Stock	40K	$1.92	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	60% of the option vested on January 22, 2023 and 40% on July 22, 2023.
F2	The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options.
F3	One-third of the option vested on October 18, 2023. The remainder of the option vests equally on October 18, 2024 and October 18, 2025.